论文部分内容阅读
目的:探讨阿奇霉素口服治疗小儿呼吸道肺炎支原体感染的临床效果及安全性。方法:选取2012年5月至2013年10月在我院就诊的144例呼吸道肺炎支原体感染患儿,随机分为观察组和对照组,每组各72例。对照组加用注射用乳糖酸红霉素静滴治疗,观察组加用阿奇霉素口服治疗。对比两组患者的治疗效果及不良反应的发生情况。结果:观察组的总有效率为94.45%,明显高于对照组的83.33%;观察组患儿各临床症状及体征的消失时间均明显短于对照组;观察组患儿不良反应的总发生率为6.95%,显著低于对照组的16.67%,差异均有统计学意义(P<0.05)。结论:相比于注射用乳糖酸红霉素静滴治疗,阿奇霉素口服治疗小儿呼吸道肺炎支原体感染疗效更佳,且具有不良反应小,用药安全,患儿的配合度高的优势。
Objective: To investigate the clinical effect and safety of oral azithromycin in treating Mycoplasma pneumoniae infection in children. Methods: A total of 144 children with respiratory tract mycoplasma pneumoniae who were treated in our hospital from May 2012 to October 2013 were randomly divided into observation group and control group with 72 cases in each group. The control group plus injection of erythromycin lactobionate intravenously, the observation group plus azithromycin oral treatment. Comparison of the two groups of patients with treatment and adverse reactions occurred. Results: The total effective rate of the observation group was 94.45%, which was significantly higher than that of the control group (83.33%). The disappearance time of clinical symptoms and signs in the observation group was significantly shorter than that of the control group. The overall incidence of adverse reactions in the observation group (6.95%), which was significantly lower than that of the control group (16.67%). The difference was statistically significant (P <0.05). Conclusion: Compared with the intravenous infusion of erythromycin lactobionate for injection, azithromycin has a better curative effect in the treatment of Mycoplasma pneumoniae infection in children and has the advantages of low adverse reaction, safe administration and high degree of coordination with children.